BioXcel Therapeutics Inc. (BTAI)
3.81
1.65 (76.39%)
At close: Mar 03, 2025, 3:59 PM
3.60
-5.51%
After-hours: Mar 03, 2025, 07:39 PM EST
No 1D chart data available
| Bid | 3.6 |
| Market Cap | 11.82M |
| Revenue (ttm) | 166.54K |
| Net Income (ttm) | -5.2M |
| EPS (ttm) | -32.64 |
| PE Ratio (ttm) | -0.12 |
| Forward PE | -0.3 |
| Analyst | Hold |
| Ask | 3.63 |
| Volume | 146,173,397 |
| Avg. Volume (20D) | 1,914,585 |
| Open | 2.37 |
| Previous Close | 2.16 |
| Day's Range | 2.37 - 6.81 |
| 52-Week Range | 1.72 - 52.80 |
| Beta | -0.01 |
About BTAI
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 8, 2018
Employees 74
Stock Exchange NASDAQ
Ticker Symbol BTAI
Analyst Forecast
According to 4 analyst ratings, the average rating for BTAI stock is "Hold." The 12-month stock price forecast is $32, which is an increase of 739.90% from the latest price.
Buy 50.00%
Hold 25.00%
Sell 25.00%
Next Earnings Release
BioXcel Therapeutics Inc. is scheduled to release its earnings on Mar 14, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
20 hours ago
BioXcel Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
3 days ago
+24.86%
BioXcel Therapeutics shares are trading higher after the company announced it regained Nasdaq listing compliance.
